Citadel Advisors’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.7M | Sell |
2,613,693
-133,452
| -5% | -$1M | ﹤0.01% | 965 |
|
|
2025
Q1 | $20.8M | Buy |
2,747,145
+64,241
| +2% | +$486K | ﹤0.01% | 874 |
|
|
2024
Q4 | $32.7M | Buy |
2,682,904
+727,647
| +37% | +$8.86M | 0.01% | 715 |
|
|
2024
Q3 | $32.7M | Buy |
1,955,257
+12,118
| +0.6% | +$203K | 0.01% | 646 |
|
|
2024
Q2 | $33.9M | Buy |
1,943,139
+833,968
| +75% | +$14.5M | 0.01% | 628 |
|
|
2024
Q1 | $18.9M | Sell |
1,109,171
-23,718
| -2% | -$404K | ﹤0.01% | 913 |
|
|
2023
Q4 | $11.5M | Buy |
1,132,889
+67,841
| +6% | +$691K | ﹤0.01% | 1138 |
|
|
2023
Q3 | $9.64M | Buy |
1,065,048
+8,697
| +0.8% | +$78.7K | ﹤0.01% | 1179 |
|
|
2023
Q2 | $11.4M | Buy |
1,056,351
+433,283
| +70% | +$4.66M | ﹤0.01% | 1126 |
|
|
2023
Q1 | $6.37M | Buy |
623,068
+377,958
| +154% | +$3.87M | ﹤0.01% | 1630 |
|
|
2022
Q4 | $2.59M | Buy |
245,110
+9,507
| +4% | +$100K | ﹤0.01% | 2355 |
|
|
2022
Q3 | $3.02M | Sell |
235,603
-133,867
| -36% | -$1.72M | ﹤0.01% | 2343 |
|
|
2022
Q2 | $4.74M | Buy |
369,470
+229,785
| +165% | +$2.95M | ﹤0.01% | 1910 |
|
|
2022
Q1 | $1.46M | Buy |
139,685
+93,204
| +201% | +$976K | ﹤0.01% | 3350 |
|
|
2021
Q4 | $717K | Sell |
46,481
-59,652
| -56% | -$920K | ﹤0.01% | 4206 |
|
|
2021
Q3 | $2.4M | Buy |
106,133
+3,025
| +3% | +$68.3K | ﹤0.01% | 2798 |
|
|
2021
Q2 | $2.66M | Sell |
103,108
-8,214
| -7% | -$212K | ﹤0.01% | 2899 |
|
|
2021
Q1 | $4.64M | Buy |
+111,322
| New | +$4.64M | ﹤0.01% | 2182 |
|